AR099833A1 - Compuesto amídico como antagonista del receptor ep4 - Google Patents
Compuesto amídico como antagonista del receptor ep4Info
- Publication number
- AR099833A1 AR099833A1 ARP150100875A ARP150100875A AR099833A1 AR 099833 A1 AR099833 A1 AR 099833A1 AR P150100875 A ARP150100875 A AR P150100875A AR P150100875 A ARP150100875 A AR P150100875A AR 099833 A1 AR099833 A1 AR 099833A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- receptor
- salt
- pharmaceutical composition
- antagonistic action
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Se presenta un compuesto que es útil como ingrediente activo de una composición farmacéutica, por ejemplo, una composición farmacéutica para tratar la insuficiencia renal crónica y/o la nefropatía diabética. Se han llevado a cabo extensos estudios sobre un compuesto con una acción antagonista del receptor EP4 y han encontrado que un compuesto amídico o una sal del mismo exhibe una acción antagonista del receptor EP4, completando de esa manera la presente. El compuesto amídico o una sal del mismo tiene acción antagonista del receptor EP4 y se lo puede utilizar como ingrediente activo de una composición farmacéutica para prevenir y/o tratar diversas enfermedades relacionadas con el EP4, por ejemplo, la insuficiencia renal crónica y/o la nefropatía diabética. Reivindicación 1: Ácido 4-[(1S)-1-({[4-bromo-1-(isoquinolin-3-ilmetil)-3-metil-1H-pirazol-5-il]carbonil}amino)etil]benzoico o una sal del mismo. Reivindicación 3: El compuesto de acuerdo con la reivindicación 2, que es un cristal de metansulfonato de ácido 4-[(1S)-1-({[4-bromo-1-(isoquinolin-3-ilmetil)-3-metil-1H-pirazol-5-iI]carbonil}amino)etil]benzoico. Reivindicación 4: El compuesto de acuerdo con la reivindicación 3, que es un cristal con una temperatura de inicio de un pico endotérmico en el análisis de DSC de 192ºC y con picos a 2q (º) = 4,7, 9,5, 12,0, 13,2, 13,7, 15,3, 18,8, 20,3, 20,9 y 22,8 en la difracción de rayos X en polvo utilizando Cu como tubo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014064590 | 2014-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099833A1 true AR099833A1 (es) | 2016-08-24 |
Family
ID=54195532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100875A AR099833A1 (es) | 2014-03-26 | 2015-03-25 | Compuesto amídico como antagonista del receptor ep4 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10106523B2 (es) |
| EP (1) | EP3124480B1 (es) |
| JP (1) | JP6428763B2 (es) |
| KR (1) | KR20160138098A (es) |
| CN (1) | CN106132945B (es) |
| AR (1) | AR099833A1 (es) |
| CA (1) | CA2943778A1 (es) |
| ES (1) | ES2684334T3 (es) |
| MX (1) | MX368098B (es) |
| PL (1) | PL3124480T3 (es) |
| PT (1) | PT3124480T (es) |
| RU (1) | RU2684906C2 (es) |
| TW (1) | TW201623277A (es) |
| WO (1) | WO2015147020A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| US11446298B2 (en) | 2017-05-18 | 2022-09-20 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| AR111941A1 (es) | 2017-05-18 | 2019-09-04 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| BR112019024114A2 (pt) | 2017-05-18 | 2020-06-02 | Idorsia Pharmaceuticals Ltd | Composto, e, métodos de modulação de uma resposta imune e de profilaxia ou tratamento de uma condição |
| KR20230107228A (ko) | 2020-11-13 | 2023-07-14 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0311247A (pt) * | 2002-05-23 | 2005-03-15 | Theratechnologies Inc | Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2 |
| JP5259592B2 (ja) | 2006-08-11 | 2013-08-07 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
| EP2460787A1 (en) * | 2007-07-03 | 2012-06-06 | Astellas Pharma Inc. | Amide compounds and their use as PGE2 antagonists. |
| CA2724077C (en) | 2008-05-14 | 2016-04-26 | Astellas Pharma Inc. | Amide compound |
| EP3061751A1 (en) | 2010-09-21 | 2016-08-31 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
-
2015
- 2015-03-24 TW TW104109378A patent/TW201623277A/zh unknown
- 2015-03-25 ES ES15770149.1T patent/ES2684334T3/es active Active
- 2015-03-25 JP JP2016510404A patent/JP6428763B2/ja active Active
- 2015-03-25 CA CA2943778A patent/CA2943778A1/en not_active Abandoned
- 2015-03-25 CN CN201580016273.8A patent/CN106132945B/zh active Active
- 2015-03-25 AR ARP150100875A patent/AR099833A1/es unknown
- 2015-03-25 EP EP15770149.1A patent/EP3124480B1/en active Active
- 2015-03-25 KR KR1020167027923A patent/KR20160138098A/ko active IP Right Grant
- 2015-03-25 MX MX2016012318A patent/MX368098B/es active IP Right Grant
- 2015-03-25 WO PCT/JP2015/059026 patent/WO2015147020A1/ja active Application Filing
- 2015-03-25 PT PT15770149T patent/PT3124480T/pt unknown
- 2015-03-25 PL PL15770149T patent/PL3124480T3/pl unknown
- 2015-03-25 US US15/127,574 patent/US10106523B2/en active Active
- 2015-03-25 RU RU2016141650A patent/RU2684906C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6428763B2 (ja) | 2018-11-28 |
| RU2684906C2 (ru) | 2019-04-16 |
| CN106132945B (zh) | 2019-04-26 |
| KR20160138098A (ko) | 2016-12-02 |
| CA2943778A1 (en) | 2015-10-01 |
| TW201623277A (zh) | 2016-07-01 |
| US20180030030A1 (en) | 2018-02-01 |
| PT3124480T (pt) | 2018-10-04 |
| JPWO2015147020A1 (ja) | 2017-04-13 |
| RU2016141650A3 (es) | 2018-11-12 |
| ES2684334T3 (es) | 2018-10-02 |
| MX2016012318A (es) | 2017-02-23 |
| EP3124480A4 (en) | 2017-11-22 |
| PL3124480T3 (pl) | 2018-10-31 |
| CN106132945A (zh) | 2016-11-16 |
| MX368098B (es) | 2019-09-19 |
| RU2016141650A (ru) | 2018-04-27 |
| US10106523B2 (en) | 2018-10-23 |
| WO2015147020A1 (ja) | 2015-10-01 |
| EP3124480A1 (en) | 2017-02-01 |
| EP3124480B1 (en) | 2018-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099833A1 (es) | Compuesto amídico como antagonista del receptor ep4 | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| CR20140472A (es) | Composicion herbicida que comprende como ingrediente activo un compuesto de uracilo | |
| DOP2015000274A (es) | Compuestos químicos | |
| MY176235A (en) | Compounds that inhibit mcl-1 protein | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| HN2010002030A (es) | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 | |
| CL2019002464A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. | |
| CR20150367A (es) | Compuestos químicos | |
| CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
| DOP2015000197A (es) | Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad agonista del receptor ¿2 adrenérgico así como actividad antagonista del receptor muscarínico m3. | |
| CL2013003816A1 (es) | Compuestos derivados de carboxamida y urea que comprende pirazol aromatico sustituido, ligantes del receptor de vanilloide; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis del dolor, migraña, enfermedad de parkinson, trastornos gastrointestinales, osteoporosis, entre otras enfermedades. | |
| GT201600269A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| BR112015030387A2 (pt) | compostos de pirazol como moduladores de fshr e usos dos mesmos | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| GT201400022A (es) | Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes | |
| BR112014001908A2 (pt) | derivados aza heterocíclicos substituídos | |
| ECSP16008797A (es) | Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos | |
| CL2015003195A1 (es) | Derivados de purina como agonistas del receptor cb2. | |
| IL240949B (en) | Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes | |
| CR20150267A (es) | 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il] 1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona como un antagonista del receptor ampa dependiente de tarp-gamma 8 | |
| NZ731607A (en) | Dihydropyrimidin-2- one compounds and medical use thereof | |
| CL2017000223A1 (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
| AR095032A1 (es) | Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |